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In vivo antimalarial activity of the endophytic actinobacteria, 
Streptomyces SUK 10
Endophytic bacteria, such as Streptomyces, have the poten-
tial to act as a source for novel bioactive molecules with me-
dicinal properties. The present study was aimed at assessing 
the antimalarial activity of crude extract isolated from vari-
ous strains of actinobacteria living endophytically in some 
Malaysian medicinal plants. Using the four day suppression 
test method on male ICR strain mice, compounds produced 
from three strains of Streptomyces (SUK8, SUK10, and SUK27) 
were tested in vivo against Plasmodium berghei PZZ1/100 in 
an antimalarial screen using crude extracts at four different 
concentrations. One of these extracts, isolated from Strepto-
myces SUK10 obtained from the bark of Shorea ovalis tree, 
showed inhibition of the test organism and was further tested 
against P. berghei-infected mice for antimalarial activity at 
different concentrations. There was a positive relationship be-
tween the survival of the infected mouse group treated with 
50 μg/kg body weight (bw) of ethyl acetate-SUK10 crude ex-
tract and the ability to inhibit the parasites growth. The par-
asite inhibition percentage for this group showed that 50% 
of the mice survived for more than 90 days after infection 
with the parasite. The nucleotide sequence and phylogenetic 
tree suggested that Streptomyces SUK10 may constitute a new 
species within the Streptomyces genus. As part of the drug 
discovery process, these promising finding may contribute 
to the medicinal and pharmaceutical field for malarial treat-
ment.
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Introduction
Climate change and population movement are among the 
factors that have contributed to an increase in disease (Pillay 
and Zambon, 1998; Espinel et al., 2001). Malaria is the most 
significant human parasitic disease that increasingly threa-
tens many of the world’s population, particularly children and 
the elderly due to the emergence of drug resistance (Joy et al., 
2003; Bray et al., 2005; Yotoko and Elisei, 2006). Chloroquine 
resistance is common in Malaysia and most parts of South 
East Asia (Wellems, 2002; Abdulelah and Zainal-Abidin, 
2007) and there is also clinical and laboratory evidence of 
resistance to sulfadoxine or pyrimethamine in combination 
as well as quinine (Wellems, 2002).
  Tropical forests in Malaysia are among the oldest on the 
planet and as many as 1,300 plants from this environment are 
claimed to have medicinal properties. However, most of them 
have not been scientifically studied (Ibrahim et al., 1994). 
Previous findings have showed that the plants used by the 
native population in Malaysia as alternative medicines pro-
vide a habitat for endophytic microorganisms (Behal, 2000; 
Strobel and Daisy, 2003; Zin et al., 2011) and may have po-
tential to treat malaria. Actinomycetes in general, and strep-
tomycetes in particular, produce over two-thirds of clinically 
useful antibiotics of natural origin (Kurosawa et al., 2000; 
Berdy, 2005; Fiedler et al., 2005). These Gram-positive bac-
teria with high G-C content, complex morphological (Flärdh 
and Buttner, 2009) and physiological differentiation (Bibb, 
2005). Various reports showed that endophytic members of 
the genus Streptomyces have the ability to inhibit a variety of 
human pathogens, including bacteria and fungi (Rajendra 
et al., 2004; Ghadin et al., 2008; Zin et al., 2010, 2011). For 
example, the endophytic strain Streptomyces NRRL 30562 
from Kennedia nigriscans produces at least one broad spec-
trum antibiotic (Coombs and Franco, 2003).
  In this study, three endophytic Streptomyces isolates named 
SUK8, SUK10, and SUK27 were obtained from the Malaysian 
plants Scindapsus hederaceus, Shorea ovalis, and Zingiber 
spectabile, respectively. The aim of the present study is to 
assess the in vivo antimalarial activity against Plasmodium 
berghei PZZ1/100 strain by administrating crude extracts 
of cultures of each endophytic bacterium.
Materials and Methods
Plant selection and sterilization technique
Plant voucher number, HM449820 for S. hederaceus, HM-
449822 (S. ovalis) and GU238266 (Z. spectabile) were sub-
mitted to the Universiti Kebangsaan Malaysia (UKM) Her-
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barium Unit to obtain a tagging code. The sterilization and 
isolation of the bacteria from the plants were modified from 
Coombs and Franco (2003). Briefly, the plants were dried at 
room temperature for 48 h before being thoroughly washed 
with tap water. Internal bark of S. hederaceus and S. ovalis 
and the external stem of Z. spectabile were cut into 5.0 cm 
long strips and washed with sterile water to remove soil par-
ticles and epiphytic microorganisms. The selected part of 
the plants were then excised and subjected to a three-step 
procedure of surface sterilization: one minute wash in 99% 
(v/v) ethanol, followed by a six minute wash in 3.5% NaClO 
(v/v) and a final three-times rinse with sterilized distilled 
water (sdH2O). The effectiveness of surface sterilization pro-
cedure was tested by plating 1.0 ml of the final rinsed sdH2O 
on to nutrient agar. After 37°C incubation for seven days, 
the sterilization procedure was assumed to be successful if 
there were no microbial growth on the agar.
Isolation and identification of the bacteria
The outer most skin of all sterilized bark and stem of the 
plants were cut out. These parts were then aseptically cut as 
cross-sections into 2 to 3 mm thin slices to allow the outer- 
most, middle, and inner-most parts of the samples to be 
placed on three different agars: actinomycete Isolation Agar 
(AIA), Starch Yeast Casein Agar (SYCA), and Water Agar 
(WA) (Castillo et al., 2002). All agars were supplemented 
with 5.0 ml of 50 μg/ml cycloheximide and 50 μg/ml nysta-
tin as antifungal agents. Bacterial growth on the agar was 
assessed after four weeks incubation at room temperature 
(RT) and identified as streptomycetes on the basis of their 
colony morphology and colour before they were subcultured 
onto International Streptomyces Project 2 (ISP2) agar for 
the next phase of study.
  The endophytic Streptomyces colonies were then macro-
scopically checked using normal light microscope under 
40× magnification. Aerial and substrate mycelium colour, 
dissolved pigment colour and spore chain morphology were 
among the macroscopic characteristics observed. Gram stain-
ing was also done to permit the visualisation of the organ-
ism’s micromorphology. All of the isolates that displayed the 
morphological characteristics of Streptomyces were then 
given their UKM’s deposition number before they were kept 
as pure stock culture at -80°C by adding five pieces of (5 × 5) 
mm thin slices of isolate mycelium to 1.0 ml of glycerol 80% 
(v/v) (Castillo et al., 2002).
Production of crude extract
Nutrient broth (Sigma-Aldrich) was prepared at different pH 
levels: 6.5, 7.0, and 7.5. To produce extracts of the isolates, 
five blocks of 5 × 5 mm ISP2 agar enriched with Streptomyces 
were cut and inoculated into 400 ml autoclaved nutrient broth 
in a 1,000 ml conical flask individually. Fermentations were 
carried out using an orbital shaker at 28°C at three different 
rotation rates; 180, 200, and 220 RPM for 19–21 days. The 
supernatant was then extracted three times using the se-
lected solvents at a ratio of 1:2 of pool supernatant. Prior to 
this, 1,200 ml of supernatant were extracted with 200 ml of 
ethyl acetate three times (Castillo et al., 2002).
In vivo antimalarial screening
All animal experiments were conducted following approval 
by the UKM Animal Ethics Committee (UKMAEC) coded 
FSK/Biomed/341. Using ICR strain male mice at 28–30 g 
body weight (bw) and aged six weeks old as the model, the 
parasite Plasmodium berghei PZZ1/100 was administered 
into the host via the intraperitoneal (IP) route. Every group 
of mice (n = 6) was housed in a stainless steel cage, treated 
at room temperature with daily ad-libitum feeds at 12–12 h 
both with and without a light period. In order to assess the 
extract activity, the four days (4D) suppression test method 
(Abdulelah and Zainal-Abidin, 2007) was applied. For the 
treatment, ethyl acetate-SUK8, -SUK10, and -SUK27 crude 
extracts were diluted with 1:10 (DMSO:dH2O). As demon-
strated by previous studies (Ata-ur-Rehman et al., 1985; Peters 
and Robinson, 1992; Anthony et al., 2005; Abdulelah and 
Zainal-Abidin, 2007), no physical side effects observed on 
the treated host with 10% of DMSO. For the positive and 
negative controls, 10 mg/kg bw of dH2O diluted quinine hy-
drochloride and 0.9% normal saline respectively were used 
(Peters and Robinson, 1992; Abdulelah and Zainal-Abidin, 
2007).
  Infected blood collected from the tip of the donor mice’s 
tail was serially diluted with Alsever’s solution to obtain 1.0 
× 106 parasitized red blood cells (RBC) before they were IP 
administered at 0.1 ml to all the tested mice (Abdulelah 
and Zainal-Abidin, 2007). Within 2 h, these mice were im-
mediately treated with 0.1 ml of ethyl acetate-crude extract 
and also 0.1 ml of both positive and negative control solu-
tions. This point was considered as day zero (D0). Without 
repeating the parasite infection, the same treatment was re-
peated for the next three days and referred to as D1, D2, 
and D3. On D4, a blood smear from the treated mice was 
stained with Giemsa to obtain parasitemia density (%) and 
parasitemia inhibition (%). The mice were also observed daily 
for survival time (day) calculated after 20 days post-infection. 
Considering that the treatment used in this study was a crude 
extract and, as documented in previous studies (Ata-ur- 
Rehman et al., 1985; Anthony et al., 2005; Abdulelah and 
Zainal-Abidin, 2007), results with a parasitemia inhibition 
of > 65% were considered as having antimalarial activity 
and the mouse group with the longest survival time consid-
ered as receiving the best treatment. The value for parasi-
temia density directly reflects the value of inhibition percen-
tage, where the higher the inhibition percentage, the better 
the treatment effect was (Abdulelah and Zainal-Abidin, 2007), 
where;
  Inhibition (%) =
Parasitemia of negative control –Parasitemia of treatment  × 100Parasitemia of negative control
  Treatment for tested and control groups by in vivo screen-
ing underwent the same procedures with five different nar-
rower concentrations of the extracts; 5, 10, 50, 100, and 200 
μg/kg bw which was implemented only for the best crude ex-
tract isolate performed in preliminary screening. Similarly, 
the best among these five concentrations was determined 
when the parasitemia inhibition was > 65% in conjunction 
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Table 1. The respective relationship between plants, its tagged voucher number, macroscopic and microscopic observation of all strains
Strain Plant Plant part Voucher number
Aerial mycelium 
colour
Substrate 
mycelium colour
Dissolved 
pigment colour
Spore chain 
morphology
Gram stain 
colour
SUK8 Scindapsus hederaceus Bark (internal) HM449820 Whitish grey Light brownish Yellow Spiral Purple
SUK10 Shorea ovalis Bark (internal) HM449822 Whitish grey Brownish yellow Yellow Spiral Purple
SUK27 Zingiber spectabile Stem (external) GU238266 White Brownish yellow Yellow Rectus Purple
with the mouse group that showed the best survival.
DNA extraction of endophytic Streptomyces isolates
The genomic DNA was isolated by neutral lysis, followed 
by phenol-chloroform extraction and precipitation with iso-
propanol. The DNA from the isolates was extracted using a 
modified protocol (Keiser et al., 2000) where 30–50 mg of 
Streptomyces mycelium was suspended with 500 μl lyso-
zyme buffer in a 1.5 ml Eppendorf tube by vortexing before 
25 μl of 50 mg/ml lysozyme and 3.0 μl of 10 mg/ml RNase 
were added and the sample vortexed for 10 sec. At the end 
of the extraction process, a Thermo Scientific Nano-Drop 
2000C machine was then used to determine the purity and 
concentration reading for the isolated DNA.
Amplification and sequencing of the 23S rDNA gene
Polymerase Chain Reaction (PCR) was performed using 
the 23S rDNA gene primer pair (P1: 5?-ACCAGGATGCT 
TAGAAG-3??corresponding to E. coli 1051–1071 nucleo-
tide sequence of 23S rDNA gene and also P2: 5?-CACTTA 
CCCCGACAAGGAAT-3??corresponding to E. coli 1957–1938 
nucleotide sequence of 23S rDNA gene). PCRs were carried 
out in 50 μl reactions containing 10 μl MyTaq buffer (5× 
PCR buffer contained 10 mM dNTPs and 25 mM MgCl2), 
1.0 μl of both 20 mM reverse and forward primer, 2.0 μl of 
5 U/μl MyTaq polymerase enzyme. Then 2.0 μl of 60.5 ng/μl 
DNA template and 34 μl deionized H2O. The PCR thermo-
cycling conditions were as follows: initial denaturation of 
DNA template at 95°C for two minutes; followed by 30 cy-
cles of denaturation at 95°C for 30 sec, primer annealing at 
54°C for 30 sec, extension at 72°C for 60 sec and a final ex-
tension at 72°C for 5 min. The resulting PCR products were 
purified by using the Wizard PCR Prep DNA purification 
kit (Promega) before being sent for sequencing at Eurofins 
UK using primers P1 and P2. The 23S rDNA sequences ob-
tained were then compared to the GenBank databases by 
using basic local alignment search tool (BLAST).
Identification of compounds
With hexane and ethyl acetate as the mobile phase A and B 
respectively, 2.8 g of selected isolate crude extract was frac-
tionated (GRACE Biotage Flash Chromatography). The ex-
tract was chromatographed over 40 g generic silica while the 
columns were detected under 245 and 310 nm of respective 
UV1 and UV2 absorptions wavelength and coupled with 
isopropanol as electron light scattering detector (ELSD) at 
5.0 mV. The elution was done at 35 ml/min for 80.0 min 
run length. The thin layer chromatography (TLC) analysis 
was done on all 22 fractions by dissolving the sample with 
appropriate solvents and was visualized using the UV light 
with short and long wavelengths of 254 nm and 350 nm, 
respectively. These fractions were selected in order to deter-
mine the optimized solvent system that lead to the visuali-
zation of the compounds observed in TLC. All of the sam-
ples obtained during the fractionation process were dissolved 
in denatured chloroform (CDCl3) and tested by NMR for 
determination of its chemical structure and configuration. 
This method was implemented using NMR AS400 for 400 
MHz and Bruker FT-NMR for 600 MHz. The fractions that 
underwent NMR experiments were subjected for 1D and 
2D 1H analysis. COSY (400 Mz), HMBC (6 h), and HMQC 
(8 h) were also further implemented for interesting fractions 
with promising characteristics (fractions 11, 15, and 20), as 
well as for 13C and DEPT (both 4 h) individually. In addition 
to the NMR profiles, high resonance liquid chromatography 
mass spectrometry (HR-LCMS) analysis (ACCELA Auto- 
Sampler) was also carried out and the data were then com-
pared with the information documented in AntiBase library 
to obtain any supportive data for determination of the com-
pound identity.
Statistical analysis
All results were expressed as the mean ± standard deviation 
(sd) from six mice per group. Due to the small sample size 
for each treated group of mice (n = 6), the Shapiro-Wilk 
test was used to analyse the significance of the antimalarial 
tests. Statistical significance was declared when P value was 
equal to or less than 0.05 (P ≤ 0.05). Since all groups were 
normally distributed, no non-parametric tests were re-
quired in this study.
Results
Identification of the bacterial strains
Micro- and macro-morphology differences between all three 
strains were used as a preliminary means to identify the iso-
lates as members of the genus Streptomyces. The relation 
between names, part of the plants, UKM’s tagged voucher 
number, the aerial and substrate mycelium colour, dissolved 
pigment colour and spore chain morphology, as well as Gram 
staining colour for all of the tested strains are shown in 
Table 1. Other than living endophytically in the same part 
of their respective plants, SUK8 and SUK10 also showed 
similarities in most of macroscopic and microscopic obser-
vations, except for their substrate mycelium colour.
Production of crude extract
After culture optimization, all strains produced most bio-
mass after 21 days fermentation in nutrient broth at pH 7.0 
and at an agitation rate of 200 RPM. Extract yields of more 
than 40 mg were only obtained from all strains with an agi-
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Table 2. Parasitemia density (%) on day-4 (D4) for treatment and control groups at four different concentrations in preliminary antimalarial screening
Group Description
Parasitemia density (%)
50# 100# 200# 400# 
Control
Positive 0.00 ± 0.0* 0.00 ± 0.0* 0.00 ± 0.0* 0.00 ± 0.0*
Negative 5.03 ± 2.1* 6.82 ± 1.6* 5.17 ± 3.0* 5.44 ± 2.4*
Treatment
SUK8 1.45 ± 0.7* 2.35 ± 4.0* 2.22 ± 0.1* 2.98 ± 3.1*
SUK10 1.32 ± 1.5* 1.08 ± 0.9*§ 1.11 ± 2.7*§ 2.64 ± 3.7*
SUK27 3.11 ± 0.8* 2.23 ± 1.0* 3.33 ± 0.3* 4.04 ± 2.3*
* Mean ± standard deviation (s.d.)
# Concentration (μg/kg)
§ P < 0.05
(A)
(B)
Fig. 1. Inhibition rate (%) on D4 (A) and survival time (day) (B) of mice 
groups treated with various concentration of ethyl acetate-SUK8, -SUK10, 
and -SUK27 crude extract, where (*) indicated P < 0.05.
tation rate of 200 RPM and nutrient broth at pH 7.0. Con-
sequently these conditions were used for 21 days to isolate 
SUK10 crude extracts with ethyl acetate for implementing 
in vivo antimalarial screening.
  To produce large amounts of crude extract, a scaled-up fer-
mentation with SUK10, the strain that exhibited the stron-
gest activity against P. berghei PZZ1/100 was then carried 
out using the best variant of pH, aeration rate and optimized 
length of fermentation. These conditions were characterized 
based on the highest amount of crude extract produced. This 
process was repeated in a 1,000 ml conical flask using the 
orbital shaker until the crude extract reached sufficient weight 
which at least 25.0 mg for in vivo antimalarial screening. At 
the end of the fermentation period, this culture was filtered 
to separate the mycelium from its supernatant and extracted 
using ethyl acetate three times before the organic solvent 
phase was pooled prior to a drying process using a rotary 
evaporator.
In vivo antimalarial screening of tested isolates
In order to determine the isolate that exhibited the best an-
timalarial activities we used three main parameters; para-
sitemia density, inhibition rate and survival time. For para-
sitemia density, the SUK10 crude extract at all concentra-
tions (50, 100, 200, and 400 μg/kg bw) exhibited the lowest 
value compared with SUK8 and SUK27 (Table 2). With the 
lowest parasitemia density at 1.08 ± 0.9%, there was a sig-
nificant difference for this parameter (P < 0.05, n = 6) at 
100 μg/kg bw between SUK10 and the other two isolates. 
The same results were also observed for the other three con-
centrations levels. Meanwhile at 400 μg/kg bw, 2.64 ± 3.7% 
was recorded as the highest value of parasitemia density of 
SUK10; however this was still lower compared with SUK8 
(2.98 ± 6.1%) and SUK27 (4.04 ± 5.3%).
  For the inhibition rate shown in (Fig. 1A), at all concen-
trations the SUK10 crude extract exhibited the highest per-
centage compared with SUK8 and SUK27. With the highest 
inhibition rate 84.14 ± 2.6% at 100 μg/kg bw, there was a 
significant difference (P < 0.05, n = 6) between SUK10 and 
the other two isolates at this concentration. As the inhibi-
tion rate at more than 65% was considered as a benchmark 
of in vivo antimalarial activity (Ata-ur-Rehman et al., 1985; 
Abdulelah and Zainal-Abidin, 2007), all the percentages ob-
served for SUK10 were higher than 70%, except 51.44 ± 0.9% 
at 400 μg/kg bw. No inhibition rates higher than 65% were 
observed for the other two isolates at all concentrations ex-
cept 71.14 ± 1.2% at 50 μg/kg bw and 67.45 ± 3.4% at 200 
μg/kg bw, both exhibited by SUK8 isolate. Despite this, these 
values were still lower than those observed from the crude 
extract of SUK10 isolate at the same concentrations.
  It was predicted that survival times of the treated mice 
would be longer at higher inhibition rates. Mice groups 
treated with the SUK10 crude extract at all concentrations 
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Fig. 2. Blood slides taken on D4 post-infection in mice no.1 after 4 days 
daily treatment with ethyl acetate-SUK10 crude extract at particular con-
centration: (A) 5 μg/kg bw, (B) 10 μg/kg bw, (C) 50 μg/kg bw, (D) 100 
μg/kg bw, (E) 200 μg/kg bw, (F) positive control of 10 mg/kg bw quinine 
hydrochloride and (G) negative control of 0.9% normal saline. All 4 main 
stages of P. berghei lifecycle were successfully captured in the infected- 
RBC of the mice consisted ring stage (R), trophozoite (T), schizont (S), 
and gametocyte (G).
Table 3. Parasitemia density (%) on day-4 (D4) for ethyl acetate-SUK10 crude extract treatment and control groups at five different concentrations in an-
timalarial screening of SUK10 isolate
Group
Parasitemia density (%)
5# 10# 50# 100# 200#
Positive control 0.00 ± 0.0* 0.00 ± 0.0* 0.00 ± 0.0* 0.00 ± 0.0* 0.00 ± 0.0*
Negative control 5.11 ± 2.1* 6.21 ± 1.6* 6.39 ± 3.2* 5.40 ± 2.4* 6.11 ± 0.7*
Treatment 2.32 ± 1.2* 2.18 ± 0.5* 1.86 ± 3.1* 1.64 ± 3.0*§ 2.01 ± 0.5*
* Mean ± standard deviation (s.d.)
# Concentration (μg/kg)
§ P < 0.05
(A)
(B)
Fig. 3. Inhibition rate (%) on D4 (A) and survival time (day) (B) of mice 
groups treated with various concentration of ethyl acetate-SUK10, where 
(*) indicated P < 0.05.
exhibited the longest survival time compared with the other 
isolates at the same concentration. In accordance with the 
inhibition rate, the mouse group treated with SUK10 crude 
extract at 100 μg/kg bw managed to survive up to 21 days 
post-infection as well as 18 and 16 days for the other con-
centrations (Fig. 1B). There was also a significant difference 
for the mice survival time (P < 0.05, n = 6) at 100 μg/kg bw 
between SUK10 and the other two strains.
In vivo antimalarial screening of SUK10
The SUK10 extract was subjected to final in vivo anti-
malarial screening with five different concentrations across 
a narrower range (5, 10, 50, 100, and 200 μg/kg bw) in order 
to determine which concentration gives the best in vivo an-
timalarial activity. With only 1.64 ± 3.0% at 100 μg/kg bw, 
there was a significant difference for parasitemia density (P 
< 0.05, n = 6) between 100 μg/kg bw and the other four 
concentrations. Nevertheless, 1.86 ± 3.1% observed for 50 
μg/kg bw was still lower compared to the other concentra-
tions (Table 3). The blood slides taken on D4 for every con-
centration of SUK10 treatments from particular mice showed 
that the distribution of four main stages of P. berghei life-
cycle were successfully captured in the infected-RBC (Fig. 
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Fig. 4. Neighbour joining phylogenetic tree 
constructed for SUK10 isolate showed that 
it was felt among the same genus cluster of 
Streptomyces as its genomic sequences is 
96% identical with Streptomyces hygroscopicus 
subsp. jinggangensis.
Table 4. The yield obtained from all isolated fractions of SUK10 crude 
extract and their compound identity
Solvent system Fraction Net weight (g) Compound
Hexane and
ethyl acetate
(H:EA = 8:2)
V1 0.1106 Long chained triglyceride fatty acid
V2 0.0271 Long chained triglyceride fatty acid
V3 0.8132 Long chained triglyceride fatty acid
V4 0.1255 Long chained triglyceride fatty acid
V5 0.0890 Long chained triglyceride fatty acid
V6 0.0393 Macrotetrolide B (C47H72O12)
V7 0.0162 Swalpamycin B (C36H58O13)
Hexane and
ethyl acetate
(H:EA = 6:4)
V8 0.0185 Milbemycin A8 (C40H60O10)
V9 0.0125 Phenalamide C (C32H45NO4)
V10 0.0301 Eicosanedioic acid (C20H38O4)
V11 0.0249 3-indole lactic acid (C11H11NO3)
V12 0.0287 Monacolin L (C19H30O4)
V13 0.0283 Platensimycin B3 (C23H27NO5)
Dichloromethane
and methanol
(DCM:M = 9:1)
V14 0.0191 Mollicellin D (C21H21ClO6)
V15 0.0162 Gancidin W (C11H18N2O2)
V16 0.0113 Gymnodimine B (C32H45NO5)
V17 0.0276 Venturicidin A (C40H66O10)
V18 0.0082 Aspereline F (C46H82N10O1)
V19 0.0300 Long chained triglyceride fatty acid
V20 0.0498 Long chained triglyceride fatty acid
V21 0.0142 Long chained triglyceride fatty acid
V22 0.0184 Long chained triglyceride fatty acid
2). This figure indicated that the complete development of 
one plasmodial’s lifecycle in suppressed vertebrate host was 
completed within four days after infection.
  Since every concentration had its own negative control 
group individually, the inhibition rate for 50 μg/kg bw was 
relatively high and gave the greatest value, although the par-
asitemia density was quite lower at 100 μg/kg bw compared 
with 50 μg/kg bw (Fig. 3A). The concentration at these two 
values, together with the concentration at 200 μg/kg bw, were 
considered as the concentrations where antimalarial activity 
could be best assessed because the value obtained at 5 μg/kg 
bw and 10 μg/kg bw was lower than 65% (Ata-ur-Rehman et 
al., 2005; Abdulelah and Zainal-Abidin, 2007). At the highest 
value, 70.89 ± 3.1%, there was a significant difference (P < 
0.05, n = 6) between 50 μg/kg bw and the other four con-
centrations.
  In this study, the longest survival time observed was 91.11 
± 0.5 days post-infection (data not shown), which was ex-
hibited by half of the total mice (n = 3) treated with 50 μg/kg 
bw ethyl acetate-SUK10 crude extract. Surprisingly, the re-
maining half of these mice (n = 3) in this group also man-
aged to survive between 55–65 days post-infection which 
was far longer than the other four groups for SUK10 at this 
phase (Fig. 3B).
Preliminary identification of SUK10 by 23S rDNA sequenc-
ing
Since SUK10 showed the most significant antimalarial ac-
tivity, the amplification of 23S rDNA gene was only done 
on this strain. SUK10 samples generated an amplicon close 
to the predicted size of 1Kb (data not shown). After sequen-
cing, this product was confirmed to be 1,006 bp in length 
with the score 97% of multiple sequence alignments. The 
BLASTN results of two independent SUK10 sequences re-
vealed that the nucleotide sequence has 94–96% identity 
with other species, with Streptomyces hygroscopicus jinggan-
gensis having the highest homology. The neighbour joining 
phylogenetic tree (Fig. 4) suggested that Streptomyces SUK10 
may constitute a new species within the Streptomyces genus. 
Due to this promising outcome, detailed characterization 
of SUK10 strain is currently being done in our laboratory 
to determine the full genome sequence of this strain.
Identification of compounds
Twenty-two fractions (V1–V22) were obtained following 
separation of spots by TLC (fraction 1–7 under development 
in 80:20 (v/v) of hexane/ethyl acetate, fraction 8–13 (60:40, 
v/v, hexane/ethyl acetate) and fraction 14–22 (90:10, v/v, 
DCM/methanol). The obtained yield and the compound 
identity name from all fractions of SUK10 crude extract are 
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Table 5. Assignment of the 1H and 13C NMR signal of GW at 400 MHz in CDCl3
Position
Gancidin W. (Helvetica Chimica Acta Vol. 92) (Bin et al., 2009) SUK10 (Gancidin W)
δH (J in Hz) δC δH (J in Hz) δC
1 C - 172.9 - 166.0
2 - - - - -
3 CH2 3.54 – 3.51 (m) 46.5 3.55 (m) 45.8
4 CH2 1.94 – 1.87 (m), 2.06 – 1.99 (m) 23.6 1.88 (m), 2.02 (m) 23.1
5 CH2 2.35 – 2.31 (m), 1.96 – 1.87 (m) 29.1 2.33 (m), 2.03 (m) 29.2
6 H–C 4.15 (br. s) 60.3 4.08 (d) 59.3
7 C - 168.9 - 170.0
8 N–H - - 6.44 (s) -
9 H–C 4.29 (t, J = 7.1Hz) 54.7 4.01 (t, J = 7.1) 53.7
10 CH2 or H–C 1.99 – 1.94 (m), 1.57 – 1.53 (m) 39.4 2.03 (m), 1.47 (m) 39.0
11 H–C, Me or CH2 2.06 – 2.01 (m) 25.7 1.76 (m) 25.0
12 Me 1.01 (d, J = 6.5) 23.4 0.97 (d, J = 6.5) 23.0
13 Me 0.97 (d, J = 6.5) 22.2 0.91 (d, J = 6.5) 22.0
Hz hertz, δH coupling constants (J) for H, δC coupling constants (J) for C, s singlet, d doublet, t triplet, m multiplet, q quadruplet, br broad.
shown in Table 4. Due to the interesting peak displayed by 
fraction 15, this fraction was also subjected for 13C and 
DEPT (600 Mz, 4 h). The pure fraction in vial number 15 
(V15) was revealed as a type of prolyl-leucyl-diketopiper-
azine namely Gancidin W (Bin et al., 2009) based on 1D 
1H-13C and 2D 1H-1H NMR analysis, COSY, HMBC, 
HMQC, and DEPT tests of NMR correlation data and 
Antibase Library data. 16.2 mg of this compound was iso-
lated as a light brownish solid with molecular formula 
(MF) C11H18N2O2 and molecular weight (MW) 210.275 at 
retention time 7.17 min. The assignment of the 1H and 13C 
NMR signal of Gancidin W are shown in Table 5.
Discussion
While the efficacy of the extracts of SUK8 and SUK27 were 
comparable for all parameters in this study, some of the 
parameters observed for SUK8 such as parasitemia density 
at 400 μg/kg bw and inhibition rate and survival time at 50 
μg/kg bw were approximately the same value as obtained 
for SUK10. It was noted that, for all parameters obtained in 
the final antimalarial screening for SUK10, survival time 
for the mouse group treated with 100 μg/kg bw was similar 
to those treated with 200 μg/kg bw. The reasons behind this 
may be multifactorial. Aside from the fact that the progre-
ssion of the erythrocytic cell cycle in Plasmodium-infected 
host is poorly understood (Prudhomme et al., 2008), every 
secondary metabolite classes contained in the crude extracts 
has their own characteristics such as active groups and po-
larity indexes (Zin et al., 2011) and also, there may be a ten-
dency to obtain more significant values for those parameters 
in particular cycles or stages of the Plasmodium life cycle. 
These factors were not considered in this study.
  Clinically, it is more practical to give the daily treatment 
with antimalarial drugs containing particular active func-
tional groups for more than seven days (Rajendra et al., 2004; 
Abdulelah and Zainal-Abidin, 2007), depending on the treat-
ment regime combination, stage of infection and type of plas-
modial species (Ernest, 1995; Foley and Tilley, 1998; Kuro-
sawa et al., 2000; Rajendra et al., 2004; Abdulelah and Zainal- 
Abidin, 2007). At the present time, the chemical structure and 
active functional groups in all tested crude extracts that are 
responsible for antimalarial activity has not yet been deter-
mined to a high level of detail.
  Considering all concentrations both in preliminary anti-
malarial screening and antimalarial screening of SUK10 ex-
tracts, all the untreated control mice died between seven and 
nine days post infection and more than 18 months post in-
fection for positive control. This was also described in pre-
vious in vivo antimalarial studies (Zainal-Abidin et al., 1985; 
Kurosawa et al., 2000; Isaka et al., 2002; Jochen et al., 2002; 
Abdulelah and Zainal-Abidin, 2007; Prudhomme et al., 2008; 
Lipsitch et al., 2010).
  In agreement with the in vitro data as well as that observed 
in other studies (Kurosawa et al., 2000; Isaka et al., 2002; 
Abdulelah and Zainal-Abidin, 2007; Prudhomme et al., 2008), 
it is possible that survival time of the treated mice might be 
longer at the higher inhibition rate value, which was also 
observed in this study. Several previous studies (Zainal- 
Abidin et al., 1985; Kurosawa et al., 2000; Jochen et al., 2002; 
Rajendra et al., 2004; Abdulelah and Zainal-Abidin, 2007; 
Prudhomme et al., 2008) found that 50–150 μg/kg bw is 
the best range of dose for the treatment of crude extract in 
order to fulfil the same parameters. This may explain why in 
this study, the parasitemia density rose up at 200 μg/kg bw 
(Table 3) before stabilizing at 100 μg/kg bw in antimalarial 
screening for SUK10 strain and the inhibition rate decreased 
at the same concentration (Fig. 3A). To support these find-
ings, some previous studies documented that SUK10 also 
exhibited very strong antimicrobial activity against Bacillus 
subtilis ATCC 6633 at inhibition percentage 76.2% and B. 
cereus ATCC 6464 (76.4%) as well as antifungal activity 
against Aspergillus fumigatus (84.6%), Rhizoctonia solani 
(94.1%), Geotrichum candidum (91.7%), Trichoderma viridae, 
and Fusarium solani (both 100%) (Ghadin et al., 2008; Zin 
et al., 2010).
  Based on the 1H NMR analyses in this study, fraction V15 
was found to contain interesting signals that corresponded to 
the major constituent. V15 at 98% purity was isolated at 16.2 
mg (0.31% yield) as light brownish solid material with a mo-
lecular weight 210.275 and molecular formula of C11H18N2O2 
854 Baba et al.
established by HR-LCMS at a retention time of 7.17 min. 
In this paper, the nomenclature Gancidin W (GW) was as-
signed for the isolated compound V15. The peak displayed 
in fraction was determined to be GW. This is a natural com-
pound of the alkaloid group (Adamczeski et al., 1995; Bin et 
al., 2009) and as such this compound is suspected to be res-
ponsible for antimalarial activity shown in this study. Natural 
compounds in the alkaloid group are among the most inves-
tigated compounds in terms of antimalarial research (Fer-
nandez et al., 2009). For instance, by using the 4D suppre-
ssive test on the mice, Cassiarin A that was isolated from the 
leaves of Cassia siamea (Leguminosae) showed an inhibi-
tory effects against P. falciparum with IC50 value of 0.02 μM 
(Ekasari et al., 2009).
  Other than that, alkaloid components isolated from the 
Bhutanese medicinal plant Corydalis calliantha (Fumariaceae) 
were used for the treatment of malaria in Bhutan. Protopine 
and Cheilanthifoline showed promising in vitro antimalarial 
activities against P. falciparum [both wild type (TM4) and 
multidrug-resistant (K1) strains, with IC50 values of 2.78 – 
4.29 μM] (Wangchuk et al., 2010). The 1H and 13C data for 
V15 (Table 5) were in accordance to the cyclodipeptide 
structure for S-prolyl-R-leucyl-diketopiperazine, previously 
isolated from the sponges Calyx cf. podatypa (Adamczeski 
et al., 1995) and Callyspongia (Bin et al., 2009). A similar 
compound, named as Gancidin W and elucidated as cyclo- 
(L-leu-L-pro) but with unknown absolute stereochemistry, 
was earlier isolated from strains of Streptomyces gancidus 
(Jain et al., 1977).
  In this study, the natural product gave an optical rotation 
of [α]D –138.2 (c = 1.0, EtOH) which was compatible with 
those isolated earlier from other Streptomyces strains (Jain 
et al., 1977). This diketopiperazine (DKP) derivative com-
pound is naturally produced by many organisms and dis-
plays a wide diversity of structures and biological functions 
(Smaoui et al., 2012). This scenario suggests that Gancidin 
W may be a useful chemical entity for the discovery and de-
velopment of new drugs. Some DKP derivatives have already 
been demonstrated to have a good biological activity such as 
antibacterial, antiviral, antitumor, fungicidal, and many more 
(Magyar et al., 1999; Belin et al., 2012). Although Gancidin W 
was previously identified in extracts from other Streptomyces 
sp. (Rhee, 2002; Ben Ameur Mehdi et al., 2004), its antimal-
arial properties have not yet been reported. On top of these 
reasons, it is highly suggested that the other compounds 
isolated in each fraction were unnecessarily tested for its an-
timalarial bioactivity since it met the principal of “Lipinski’s 
Rule of Five” or Rule of Five (Veber et al., 2002). Since al-
most all isolated fractions in this study were represented the 
compounds which were almost and over 500 Dalton of its 
molecular mass (including long chained triglyceride fatty 
acid), unlikeliness, the property as bioactive drug among them 
seem to be absented.
  Consequently through the significance level of statistical 
tests, the consistency of the values for malarial inhibition in 
this study are promising and the results reported in this pa-
per indicate that Streptomyces SUK10 has good potential as 
producing an antimalarial agent.
Acknowledgements
This work was supported by the grant provided by Ministry 
of Higher Education Malaysia (FRGS/1/2011/ST/UKM/02/1) 
and the Universiti Kebangsaan Malaysia (UKM-GUP-TKP- 
08-22-074). We also appreciated the financial support from 
International Islamic University Malaysia and Tunku Na-
quiyuddin Foundation of Malaysia for making this study 
possible. We would also like to express our special apprecia-
tion to the laboratory management organisation of Strath-
clyde Institute of Pharmacy and Biomedical Sciences (SIPBS), 
University of Strathclyde, Glasgow UK, for their technical 
support and gentle permissions for us to use their laboratory 
instruments and materials.
References
Abdulelah, H.A. and Zainal-Abidin, B.A.H. 2007. In vivo antimala-
rial test of Nigeila sativa (black seed). Am. J. Pharmacol. Toxicol. 
2, 46–50.
Adamczeski, M., Reed, A.R., and Crews, P. 1995. New and known 
diketopiperazines from the Caribbean sponge, Calyx cf. podatypa. 
J. Nat. Prod. 58, 201–208.
Anthony, P.J., Fyfe, L., and Smith, H. 2005. Plant active compo-
nents-a source for anti-parasitic agents. Trend Parasitol. 21, 462– 
468.
Ata-ur-Rehman, S., Malik, H., Cun, H., and Clardy, J. 1985. Isola-
tion and structure determination of nigellicine, a novel alkaloid 
from seeds of Nigella sativa. Tetrahedron Lett. 26, 2759–2762.
Behal, V. 2000. Bioactive products from Streptomyces. Adv. Appl. 
Microbiol. 47, 113–157.
Belin, P., Moutiez, M., Lautru, S., Seguin, J., Pernodet, J.L., and 
Gondry, M. 2012. The nonribosomal synthesis of diketopipera-
zines in tRNA-dependent cyclodipeptide synthase pathways. Nat. 
Prod. Rep. 29, 961–979.
Ben Ameur Mehdi, R., Mellouli, L., Chabchoub, F., Fotso, S., and 
Bejar, S. 2004. Purification and structure elucidation of two bi-
ologically active molecules from a new isolated Streptomyces sp. 
US24 strain. Chem. Nat. Comp. 40, 510–513.
Berdy, J. 2005. Bioactive microbial metabolites. J. Antibiot. 58, 
1–26.
Bibb, M.J. 2005. Regulation of secondary metabolism in Streptomy-
cetes. Curr. Opin. Microbiol. 8, 208–215.
Bin, Y., Junde, D., Xuefeng, Z., Xianwen, Y., Kyung, J.L., Lishu, W., 
Si, Z., and Yonghong, L. 2009. Proline-containing dipeptides from 
a marine sponge of a Callyspongia species. Helv. Chim. Acta. 92, 
1112–1117.
Bray, P.G., Ward, S.A., and O’Neill, P.M. 2005. Quinolines and ar-
temisinin: chemistry, biology and history. Curr. Top. Microbiol. 
Immunol. 295, 3–38.
Castillo, U.F., Strobel, G.A., Ford, E.J., Hess, W.M., Porter, H., 
Jensen, J.B., Albert, H., Robison, R., Condron, M.A.M., Teplow, 
D.B., et al. 2002. Munumbicins, wide spectrum antibiotics pro-
duced by Streptomyces (NRRL 30562) endophytic on Kennedia 
nigriscans. Microbiology 148, 2675– 2685.
Coombs, J.T. and Franco, M.M. 2003. Isolation and identification 
of Actinobacteria from surface-sterilized wheat roots. Appl. 
Environ. Microbiol. 69, 5603–5608.
Ekasari, W., Widyawaruyanti, A., Zaini, N.C., Syafruddin, D., Honda, 
T., and Morita, H. 2009. Antimalarial activity of Cassiarin from 
the leaves of Cassia siamea. Heterocycles 78, 1831–1836.
Ernest, E.M.C. 1995. Advantages and limits of in-vivo screening 
test. Ann. Occup. Hygiene 39, 727–735.
Espinel, M.A., Laszlo, A., Simonsen, L., Boulahbal, F., Kim, S.J., 
Antimalarial activity of Streptomyces SUK 10 855
Reniero, A., Hoffner, S., Rieder, H.L., Binkin, N., Dye, C., et al. 
2001. Global trends in resistance to antituberculosis drugs. N. 
Engl. J. Med. 344, 1294–1303.
Fernandez, L.S., Buchanan, M.S., Carroll, A.R., Feng, Y.J., Quinn, 
R.J., and Avery, V.M. 2009. Flinderoles A-C: Antimalarial bis- 
indole alkaloids from Flindersia species. Org. Lett. 11, 329–332.
Fiedler, H.P., Bruntner, C., Bull, A.T., Ward, A.C., Goodfellow, M., 
Potterat, O., Puder, C., and Mihm, G. 2005. Marine actinomy-
cetes as a source of novel secondary metabolites. Antonie van 
Leeuwenhoek 87, 37–42.
Flärdh, K. and Buttner, M.J. 2009. Streptomyces morphogenetics: 
dissecting differentiation in a filamentous bacterium. Nat. Rev. 
Microbiol. 7, 36–49.
Foley, M. and Tilley, L. 1998. Quinoline antimalarials: Mechanisms 
of action and resistance and prospects for new agents. Pharmacol. 
Ther. 79, 55–87.
Ghadin, N., Zin, N.M., Sabaratnam, V., Badya, N., Basri, D.F., Lian, 
H.H., and Sidik, N.M. 2008. Isolation and characterization of a 
novel endophytic Streptomyces SUK 06 with antimicrobial acti-
vity from Malaysian plants. Asian J. Plant Sci. 7, 189–194.
Ibrahim, J., Mat Ali, R., and Goh, S.H. 1994. Toxic and antifungal 
properties of the essential oils of Cinnamomum species from 
Peninsular Malaysia. J. Trop. Forest Sci. 6, 286–292.
Isaka, M., Jaturapat, A., Kramyu, J., Tanticharoen, M., and Theb-
taranonth, Y. 2002. Potent in vitro antimalarial activity of met-
acycloprodigiosin isolated from Streptomyces spectabilis BCC4785. 
Antimicrob. Agents Chemother. 46, 1112–1113.
Jain, T.C., Dingerdissen, J.J., and Weisbach, J.A. 1977. Isolation and 
structure elucidation of Gancidin W. Heterocycles 7, 341–346.
Jochen, W., Dajana, H., David, B.H., Ewald, B., and Hassan-Jomaa, 
A. 2002. In vitro and in vivo synergy of fosmidomycin, a novel 
antimalarial drug, with clindamycin. Antimicrob. Agents Chemo-
ther. 46, 2889–2894.
Joy, D., Feng, X., and Mu, J. 2003. Early origin and recent expansion 
of Plasmodium falciparum. Science300 5617, 318–321.
Keiser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., and Hopwood, 
D.A. 2000. Practical Streptomyces Genetics (2nd ed.). John Innes 
Foundation. Norwich, England.
Kurosawa, Y., Dorn, A., Kitsuji-Shirane, M., Shimada, H., Satoh, T., 
Matile, H., Hofheinz, W., Masciadri, R., Kansy, M., and Ridley, 
R.G. 2000. Hematin polimerization assay as a high-throughput 
screen for identification of new antimalarial pharmacophores. 
Antimicrob. Agents Chemother. 44, 2638–2644.
Lipsitch, M., Tchetgen, E., and Cohen, T. 2010. Negative controls: 
A tools of detecting confounding and bias in observational studies. 
Epidemiology 21, 383–388.
Magyar, A., Zhang, X., Abdi, F., Kohn, H., and Widger, W. 1999. 
Identifying the bicyclomycin binding domain through bioche-
mical analysis of antibiotic-resistant Rho proteins. J. Biol. Chem. 
274, 7316–7324.
Peters, W. and Robinson, B.L. 1992. The chemotherapy of rodent 
malaria XLVII: studies on pyronaridine and other mannich base 
antimalarials. Ann. Trop. Med. Parasitol. 86, 455–465.
Pillay, D. and Zambon, M. 1998. Antiviral drug resistance. British 
Med. J. 317, 660–662.
Prudhomme, J., McDaniel, E., Ponts, N., Bertani, S., Fenical, W., 
Jensen, P., and Karine, L.R. 2008. Marine Actinomycete: A new 
source of compounds against the human malarial parasite. PLoS 
One 3, e2335.
Rajendra, P.M., Elisabeth, H., Oliver, K., Heinz, H.F., Armin, M., 
Andreas, B., and Hartmut, L. 2004. Anti-cancer and antibacterial 
trioxacarcins with high anti-malarial activity from a marine 
Streptomycete and their absolute stereochemistry. J. Antibiot. 
57, 771–779.
Rhee, K.H. 2002. Isolation and characterization of Streptomyces 
sp. KH-614 producing anti-VRE (vancomycin-resistant entero-
cocci) antibiotics. J. Gen. Appl. Microbiol. 48, 321–327.
Smaoui, S., Mathieu, F., Elleuch, L., Coppel, Y., Merlina, G., Karray- 
Rebai, I., and Mellouli, I. 2012. Taxonomy, purification and 
chemical characterization of four bioactive compounds from new 
Streptomyces sp. TN256 strain. World J. Microbiol. Biotechnol. 
28, 793–804.
Strobel, G. and Daisy, B. 2003. Bioprospecting for microbial en-
dophytes and their natural products microbial. Microbiol. Mol. 
Biol. Rev. 67, 491–502.
Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., 
and Kopple, K.D. 2002. Molecular properties that influence the 
oral bioavailability of drug candidates. J. Med. Chem. 45, 2615– 
2623.
Wangchuk, P., Bremner, J., Samten, B., Rattanajak, R., and Kam-
chonwongpaisan, S. 2010. Antiplasmodial agents from the Bhu-
tanese medicinal plant Corydalis calliantha. Phytother. Res. 24, 
481–485.
Wellems, T.E. 2002. Plasmodium chloroquine resistance and the 
search for a replacement antimalarial drug. Science298 5591, 
124–126.
Yotoko, K.S.C. and Elisei, C. 2006. Malaria parasites (Apicomplexa, 
Haematozoea) and their relationships with their hosts: is there 
an evolutionary cost for the specialization. J. Zool. System. Evol. 
Res. 44, 265–270.
Zainal-Abidin, B.A.H., Noorakmal, Z., and Othman, O. 1985. Ph. D. 
Thesis. National University of Malaysia, UKM Bangi Selangor, 
Malaysia.
Zin, N.M., Loi, C.S., Sarmin, N.M., and Rosli, A.N. 2010. Cultiva-
tion-dependent characterization of endophytic actinomycetes. 
Res. J. Microbiol. 5, 717–724.
Zin, N.M., Ng, K.T., Sarmin, N.I., Getha, K., and Tan, G.Y. 2011. 
Anti-trypanosoma activity of endophytic Streptomycete. Curr. 
Res. Bacteriol. 4, 1–8.
